• Explore /
  • Poster
  • / A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.

A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors.

Abstract Poster

Authors

null

Kim Anna Reiss

University of Pennsylvania Abramson Cancer Center, Philadelphia, PA

Kim Anna Reiss , Yuan Yuan , Naoto T. Ueno , Melissa Lynne Johnson , Saar Gill , Elizabeth Claire Dees , Joseph Chao , Mathew Angelos , Jonathan Stuart Serody , Saul Priceman , Debora Barton , Ramona F. Swaby , Amy Ronczka , Thomas Condamine , Daniel Cushing , Rehman Qureshi , Madison Kremp , Michael Klichinsky , Yara Abdou , Olga Shestova

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Cellular Immmunotherapy

Clinical Trial Registration Number

NCT04660929

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS2677)

DOI

10.1200/JCO.2022.40.16_suppl.TPS2677

Abstract #

TPS2677

Poster Bd #

327b

Abstract Disclosures

Similar Posters

First Author: Kim Anna Reiss

First Author: Joshua Bauml

First Author: Yara Abdou

First Author: Shanshan Jin